Results from the GeparX clinical trial demonstrated that neoadjuvant denosumab in combination with nab‐paclitaxel did not increase the pathological complete response in patients with early BC, not even in patients with RANK+ early BC, but survival remains to be evaluated (Blohmer et al, 2022). The gene discussed is TNFRSF11A; the disease is breast cancer.